

# Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients

|                                        |                                                              |                                                      |
|----------------------------------------|--------------------------------------------------------------|------------------------------------------------------|
| <b>Submission date</b><br>07/08/2005   | <b>Recruitment status</b><br>No longer recruiting            | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>11/08/2005 | <b>Overall study status</b><br>Completed                     | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>25/09/2009       | <b>Condition category</b><br>Urological and Genital Diseases | <input type="checkbox"/> Statistical analysis plan   |
|                                        |                                                              | <input type="checkbox"/> Results                     |
|                                        |                                                              | <input type="checkbox"/> Individual participant data |
|                                        |                                                              | <input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Hamid Tayebi Khosroshahi

### Contact details

Dialysis Center  
Imam Hospital  
Daneshgah Street  
Tabriz  
Iran  
+98 411 3344339  
drtayebikh@yahoo.com

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N/A

# Study information

## Scientific Title

## Acronym

Carnitine-Epo

## Study objectives

Anemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Chronic Renal Failure (End-Stage Renal Disease [ESRD])

## Interventions

1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20)
2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15)

## Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Erythropoietin, L-Carnitine

**Primary outcome measure**

Haemoglobin level

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/03/2003

**Completion date**

01/03/2005

## Eligibility

**Key inclusion criteria**

1. Dialysis for more than 6 months
2. Hb less than 11 g/dl

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

50

**Key exclusion criteria**

1. Active infectious disease
2. Active bleeding disorders

**Date of first enrolment**

01/03/2003

**Date of final enrolment**

01/03/2005

## Locations

**Countries of recruitment**

Iran

**Study participating centre**

Dialysis Center

Tabriz

Iran

## Sponsor information

**Organisation**

Tabriz University of Medical Sciences (Iran)

**Sponsor details**

Daneshgah Street

Tabriz

Iran

**Sponsor type**

University/education

**Website**

<http://www.tbzmed.ac.ir>

**ROR**

<https://ror.org/04krpx645>

## Funder(s)

**Funder type**

University/education

**Funder Name**

Tabriz University of Medical Sciences (Iran)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration